Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD).
“Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials,” says Paul Radspinner, President & Chief Executive Officer of FluGen. “The project looks to hold tremendous promise.”
Through a proprietary design of experiments, the Predictive Oncology biologics team will be developing a formulation that is soluble and stable in a refrigerated state, which is a vital part in the drug development process. Most importantly, this addresses the need for a longer vaccine shelf-life to support global distribution including remote locations. Predictive Oncology’s biologics capabilities are uniquely suited to help achieve maximum stability, one of the initial critical milestones.
“We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market,” notes Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. “Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.